OKYO Pharma Limited OKYO 深 沪
已收盘 05-08 16:00:00 美东时间
1.63
+0.010
+0.62%
华盛通- 最 高1.65
- 今 开1.63
- 成交量 4.46万股
- 最 低 1.61
- 昨 收 1.62
- 总市值 8554.12万
- 52周最高 3.349
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 1.44
- 委 比 95.50%
- 总股本 5247.93万
- 历史最高 7.00
- 量 比 0.63
- 振 幅 2.47%
- 历史最低 0.8075
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多9 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 98.6% to $0.3...
04-08 20:05
OKYO Pharma Executive Buys More Shares, Signals Confidence
OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it
03-19 19:13
OKYO Pharma Announces Director Acquires Shares
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on NASDAQ at $1.61, increasing his total holding to 31,201 shares. The company is advancing Urcosimod, a lipid-conjugated chemerin peptide agonist, which has demonstrated anti-inflammatory and pain-redu...
03-19 14:00
OKYO Pharma Reports Trial Results For Eye Pain Treatment
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today
03-18 19:10
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
OKYO Pharma announces positive results from Phase 2a trial of urcosimod for neuropathic corneal pain (NCP), showing significant pain reduction and improved quality of life for patients. The exploratory analysis revealed enhanced emotional well-being and daily life satisfaction compared to placebo. With no FDA-approved treatments for NCP, OKYO plans confirmatory studies, including a Phase 2b/3 trial. These findings highlight urcosimod's potential ...
03-18 11:00
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On February...
02-24 00:29
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
OKYO Pharma announced that its abstract on urcosimod, a novel eye-drop therapy for neuropathic corneal pain (NCP), has been accepted for presentation at ARVO 2026. The Phase 2a trial showed meaningful pain reduction and improved quality of life for NCP patients. Urcosimod, with FDA Fast Track designation, is set to advance to a Phase 2b/3 trial. OKYO aims to address an unmet need in NCP treatment.
02-23 16:00
美股大行评级 | 潜在涨幅214.14%！HC Wainwright & Co.：Ardelyx获机构升目标价至18美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Ardelyx"买入"评级，目标价从10美元升至18美元；Truist Securities：维持Praxis Precision Medicine"买入"评级，目标价从500美元升至700美元
02-23 08:56
Piper Sandler Initiates Coverage On OKYO Pharma with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Biren Amin initiates coverage on OKYO Pharma (NASDAQ:OKYO) with a Overweight rating and announces Price Target of $7.
02-20 18:09
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 19.6% to $1.4 during Frid...
02-13 20:05
